The blood-brain barrier (BBB) represents the most significant obstacle to delivering therapeutics for [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), and [FTD](/diseases/frontotemporal-dementia). This specialized interface of brain endothelial cells restricts the passage of ~98% of small molecule drugs and virtually all biologics, necessitating innovative technologies to enable effective CNS drug delivery["@bloodbrain2023"][@engineered2022].
Relationship to Neurodegenerative Diseases
...
Introduction
Mermaid diagram (expand to render)
The blood-brain barrier (BBB) represents the most significant obstacle to delivering therapeutics for [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), and [FTD](/diseases/frontotemporal-dementia). This specialized interface of brain endothelial cells restricts the passage of ~98% of small molecule drugs and virtually all biologics, necessitating innovative technologies to enable effective CNS drug delivery["@bloodbrain2023"][@engineered2022].
Relationship to Neurodegenerative Diseases
BBB crossing is critical for delivering [tau](/proteins/tau)-targeting antibodies, [alpha-synuclein](/proteins/alpha-synuclein)-targeting therapies, [amyloid-beta](/proteins/amyloid-beta)-targeting biologics, and [TDP-43](/proteins/tardbp-protein) modulators to the brain. The [neuroinflammation](/mechanisms/neuroinflammation) driven by [microglial](/cell-types/microglia) activation in [Alzheimer's disease](/diseases/alzheimers-disease) is exacerbated by impaired [blood-brain barrier](/entities/blood-brain-barrier) function. Similarly, [Parkinson's disease](/diseases/parkinsons-disease) shows early BBB disruption in the [substantia nigra](/brain-regions/substantia-nigra), complicating therapeutic delivery. In [ALS](/diseases/amyotrophic-lateral-sclerosis), the BBB breakdown enables peripheral immune infiltration that accelerates motor neuron degeneration. The [APOE](/genes/apoe) gene, particularly the ε4 allele, is associated with impaired BBB integrity in [Alzheimer's disease](/diseases/alzheimers-disease), creating additional challenges for therapeutic delivery. Targeting the [neurovascular unit](/mechanisms/neurovascular-coupling) may restore BBB function while enabling drug delivery.
The Blood-Brain Barrier
Structure and Function
Tight junctions: Formed by claudins, occludin, and junctional adhesion molecules
Endothelial cells: Specialized cells with low pinocytic activity
Astrocyte end-feet: Provide signaling support for barrier function
Transport Mechanisms
Passive diffusion: Only small, lipophilic molecules (<400 Da) cross efficiently
Carrier-mediated transport: Endogenous transporters for glucose, amino acids
Receptor-mediated transcytosis: For large molecules like transferrin, insulin
Absorptive-mediated transcytosis: For cationic proteins
Crossing Technologies
1. Receptor-Mediated Transcytosis (RMT) Platforms
Transferrin Receptor Targeting
Mechanism: Exploits endogenous transferrin receptor (TfR) for brain delivery across the [blood-brain barrier](/entities/blood-brain-barrier) in the [cerebral cortex](/brain-regions/cerebral-cortex)
Types: Liposomes, polymeric nanoparticles, dendrimers for delivery of [antibodies](/therapeutics/immunotherapy-neurodegeneration) to the [brain](/brain-regions/overview)
Advantages: Protects cargo, enables targeted delivery via [autophagy](/mechanisms/autophagy) pathways
Challenge: Manufacturing and reproducibility for clinical use in [ALS](/diseases/amyotrophic-lateral-sclerosis)
4. Physical Delivery Methods
Focused Ultrasound with Microbubbles
Mechanism: Ultrasound opens BBB temporarily using [cerebral cortex](/brain-regions/cerebral-cortex) targeting
Applications: Enabling [AAV gene therapy](/therapeutics/aav-gene-therapy-neurodegeneration), antibody delivery for [tau](/proteins/tau) pathology
Status: Clinical trials for [Alzheimer's disease](/diseases/alzheimers-disease) via [blood-brain barrier](/entities/blood-brain-barrier) modulation
Dose reduction: More efficient delivery lowers required doses
Expanded therapeutic options: Enables new drug modalities
Challenges
Technical complexity: Engineering reliable crossing mechanisms that maintain [blood-brain barrier](/entities/blood-brain-barrier) integrity while enabling drug delivery to [neurons](/cell-types/neurons)
Reproducibility: Manufacturing consistent products for [tau](/proteins/tau) and [alpha-synuclein](/proteins/alpha-synuclein) targeting in [Alzheimer's](/diseases/alzheimers-disease) and [Parkinson's](/diseases/parkinsons-disease)
Safety concerns: Potential for off-target delivery triggering [neuroinflammation](/mechanisms/neuroinflammation) via [microglial](/cell-types/microglia) activation
Regulatory hurdles: Novel platforms require extensive characterization for [amyloid-beta](/proteins/amyloid-beta) immunotherapies
Distribution: Achieving uniform brain coverage to [hippocampus](/brain-regions/hippocampus), [basal ganglia](/brain-regions/basal-ganglia), and [substantia nigra](/brain-regions/substantia-nigra)
Redosing: Pre-existing antibodies may block repeat dosing in [immunotherapy](/therapeutics/immunotherapy-neurodegeneration) approaches
Age-related changes: [Aging](/mechanisms/aging) reduces BBB integrity while also impairing transcytosis mechanisms
Disease-specific alterations: [Microvascular](/cell-types/cerebral-microvascular-endothelial-cells) changes in [vascular dementia](/diseases/vascular-dementia) differ from [Alzheimer's disease](/diseases/alzheimers-disease)